Burden of First and Recurrent Cardiovascular Events among Patients with Hyperlipidemia

Clinical Cardiology

Volumn 38, Issue 8, 2015, Pages 483-491

  Punekar, Rajeshwari S ^a   Fox, Kathleen M ^b   Richhariya, Akshara ^c   Fisher, Maxine D ^a   Cziraky, Mark ^a   Gandra, Shravanthi R ^c   Toth, Peter P ^d  

^a HEALTHCORE INC   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

^d CGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CODING; PRIMARY PREVENTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; SECONDARY PREVENTION; ADOLESCENT; CARDIOVASCULAR DISEASES; COMPLICATION; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84939465627     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22428     Document Type: Article

References (19)

1. Go AS, Mozaffarian D, Roger VL, et al., Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014; 129: e28-e292.
2. National Cholesterol Education Program. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute. NIH publication no. 01-3670.
3. Duh MS, Fulcher NM, White LA, et al., Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertens. 2009; 3: 403-415.
4. O'Sullivan AK, Rubin J, Nyambose J, et al., Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011; 29: 693-704.
5. Eisenstein EL, Shaw LK, Anstrom KJ, et al., Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care. 2001: 39: 824-835.
6. Straka RJ, Liu LZ, Girase PS, et al., Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009; 8: 53.
7. Ohlsfeldt RL, Gandhi SK, Fox KM, et al., Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ. 2010; 13: 500-507.
8. Chapman RH, Liu LZ, Girase PG, et al., Determining initial and follow-up costs of cardiovascular events in a US managed-care population. BMC Cardiovasc Disord. 2011; 11: 11.
9. Etemad LR, McCollam PL,. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm. 2005; 11: 300-306.
10. Stone NJ, Robinson JG, Lichtenstein AH, et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(25 suppl 2):S46-S48]. Circulation. 2014; 129 (25 suppl 2): S1-S45.
11. US Department of Labor, Bureau of Labor Statistics. Series CUUR0000SAM and CUUR0000SAM2. http://www.bls.gov/cpi/home.htm. Accessed November 8, 2014.
12. Parsons LS,. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed July 14, 2014.
13. Austin PC,. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28: 3083-3107.
14. Austin PC,. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009; 38: 1228-1234.
15. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
16. Rosenson RS, Kent ST, Brown TM, et al., Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015; 65: 270-277.
17. Virani SS, Woodard LD, Akeroyd JM, et al., Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014; 37: 653-659.
18. Vodonos A, Ostapenko I, Toledano R, et al., Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade? Eur J Intern Med. 2015; 26: 268-272.
19. Halcox JP, Tubach F, Lopez-Garcia E, et al., Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PloS One. 2015; 10: e0115279.